Bicara Therapeutics (NASDAQ:BCAX) said new data to be presented at the 2026 American Society of Clinical Oncology annual meeting support the clinical profile of ficerafusp alfa, also referred to by the company as Ficara, in first-line recurrent or metastatic HPV-negative head and neck cancer.
On an investor call, Chief Executive Officer Claire Mazumdar said the ASCO update includes two posters and represents “the most comprehensive and mature clinical data set” the company has assembled for ficerafusp alfa in this setting. The data span approximately 90 patients across three dose cohorts, with up to three years of follow-up at the 1,500 milligram weekly dose now being evaluated in the company’s pivotal Phase III FORTIFY-HN01 study.
